CHD5 Inhibits Metastasis of Neuroblastoma

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2021 Nov 18

PMID 34789839

Citations 12

Authors

Astrid K Laut

Carmen Dorneburg

Axel Furstberger

Thomas F E Barth

Hans A Kestler

Klaus-Michael Debatin

Christian Beltinger

Affiliations

Soon will be listed here.

Abstract

CHD5, a tumor suppressor at 1p36, is frequently lost or silenced in poor prognosis neuroblastoma (NB) and many adult cancers. The role of CHD5 in metastasis is unknown. We confirm that low expression of CHD5 is associated with stage 4 NB. Forced expression of CHD5 in NB cell lines with 1p loss inhibited key aspects of the metastatic cascade in vitro: anchorage-independent growth, migration, and invasion. In vivo, formation of bone marrow and liver metastases developing from intravenously injected NB cells was delayed and decreased by forced CHD5 expression. Genome-wide mRNA sequencing revealed reduction of genes and gene sets associated with metastasis when CHD5 was overexpressed. Known metastasis-suppressing genes preferentially upregulated in CHD5-overexpressing NB cells included PLCL1. In patient NB, low expression of PLCL1was associated with metastatic disease and poor survival. Knockdown of PLCL1 and of p53 in IMR5 NB cells overexpressing CHD5 reversed CHD5-induced inhibition of invasion and migration in vitro. In summary, CHD5 is a metastasis suppressor in NB.

Citing Articles

Integrated analysis of single-cell and bulk RNA-sequencing reveals a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in gastric cancer.

Sun J, Kong C, Ye Y, Wang Q, Qu X, Jia L Sci Rep. 2024; 14(1):7648.

PMID: 38561388 PMC: 10985121. DOI: 10.1038/s41598-024-57714-7.

Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor.

Jablonowski C, Quarni W, Singh S, Tan H, Hewa Bostanthirige D, Jin H Elife. 2024; 12.

PMID: 38488852 PMC: 10942784. DOI: 10.7554/eLife.90993.

Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.

Xia Y, Wang C, Li X, Gao M, Hogg H, Tunthanathip T Transl Pediatr. 2024; 13(1):91-109.

PMID: 38323183 PMC: 10839279. DOI: 10.21037/tp-23-582.

Epigenetic Dysregulation in -Amplified Neuroblastoma.

Epp S, Chuah S, Halasz M Int J Mol Sci. 2023; 24(23).

PMID: 38069407 PMC: 10707345. DOI: 10.3390/ijms242317085.

Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.

Wang H, Wang X, Xu L Ital J Pediatr. 2023; 49(1):145.

PMID: 37904225 PMC: 10617224. DOI: 10.1186/s13052-023-01549-x.

References

Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

Matthay K, Maris J, Schleiermacher G, Nakagawara A, Mackall C, Diller L . Neuroblastoma. Nat Rev Dis Primers. 2016; 2:16078. DOI: 10.1038/nrdp.2016.78. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

Byrne F, Yang L, Phillips P, Hansford L, Fletcher J, Ormandy C . RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. Oncogene. 2013; 33(7):882-90. DOI: 10.1038/onc.2013.11. View

Delloye-Bourgeois C, Bertin L, Thoinet K, Jarrosson L, Kindbeiter K, Buffet T . Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma. Cancer Cell. 2017; 32(4):427-443.e8. DOI: 10.1016/j.ccell.2017.09.006. View

Fife C, Sagnella S, Teo W, Pouha S, Byrne F, Yeap Y . Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration. Oncogene. 2016; 36(4):501-511. DOI: 10.1038/onc.2016.220. View

Zhu S, Zhang X, Weichert-Leahey N, Dong Z, Zhang C, Lopez G . LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell. 2017; 32(3):310-323.e5. PMC: 5605802. DOI: 10.1016/j.ccell.2017.08.002. View

Wu P, Yu I, Lin Y, Chang Y, Chen C, Lin K . Activation of Aryl Hydrocarbon Receptor by Kynurenine Impairs Progression and Metastasis of Neuroblastoma. Cancer Res. 2019; 79(21):5550-5562. DOI: 10.1158/0008-5472.CAN-18-3272. View

10.

Chen D, Cox J, Annam J, Weingart M, Essien G, Rathi K . LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase. Neoplasia. 2020; 22(6):231-241. PMC: 7186370. DOI: 10.1016/j.neo.2020.04.001. View

11.

Xiang X, Zhao X, Qu H, Li D, Yang D, Pu J . Hepatocyte nuclear factor 4 alpha promotes the invasion, metastasis and angiogenesis of neuroblastoma cells via targeting matrix metalloproteinase 14. Cancer Lett. 2015; 359(2):187-97. DOI: 10.1016/j.canlet.2015.01.008. View

12.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R . MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget. 2016; 7(41):66344-66359. PMC: 5341807. DOI: 10.18632/oncotarget.11662. View

13.

Seong B, Fathers K, Hallett R, Yung C, Stein L, Mouaaz S . A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis. Cancer Res. 2016; 77(3):696-706. DOI: 10.1158/0008-5472.CAN-16-1502. View

14.

Bhoopathi P, Pradhan A, Bacolod M, Emdad L, Sarkar D, Das S . Regulation of neuroblastoma migration, invasion, and in vivo metastasis by genetic and pharmacological manipulation of MDA-9/Syntenin. Oncogene. 2019; 38(41):6781-6793. PMC: 6786950. DOI: 10.1038/s41388-019-0920-5. View

15.

Cheng N, van Roy N, Chan A, Beitsma M, Westerveld A, Speleman F . Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. Oncogene. 1995; 10(2):291-7. View

16.

Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G . Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet. 1995; 4(4):535-9. DOI: 10.1093/hmg/4.4.535. View

17.

White P, Maris J, Beltinger C, SULMAN E, Marshall H, Fujimori M . A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A. 1995; 92(12):5520-4. PMC: 41727. DOI: 10.1073/pnas.92.12.5520. View

18.

Gehring M, Berthold F, Edler L, Schwab M, Amler L . The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res. 1995; 55(22):5366-9. View

19.

Martinsson T, Sjoberg R, Hedborg F, Kogner P . Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res. 1995; 55(23):5681-6. View

20.

White P, Maris J, Sulman E, Jensen S, Kyemba S, Beltinger C . Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma. Eur J Cancer. 1998; 33(12):1957-61. DOI: 10.1016/s0959-8049(97)00311-0. View